Find information on thousands of medical conditions and prescription drugs.

Iontocaine

Iontocaine, known by the brand name Numby, is local anesthetic administered via iontophoresis through the skin. It can numb up to 10mm of skin as quick as 10 minutes. It is a 2% lidocaine, 0.01 mg/ml epinephrine solution. It is currently only manufactured by IOMED, Inc.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


IOMED Exhibits Numby Stuff for Painless Needle Insertion at the American Red Cross' Blood Services 50th Anniversary Tour
From Business Wire, 5/28/98

SALT LAKE CITY--(BUSINESS WIRE)--May 28, 1998--IOMED Inc., (AMEX:IOX) exhibited its Numby Stuff(R) needle-free method of delivering local dermal anesthesia at the American Red Cross' Blood Services 50th Anniversary cross-country tour.

IOMED(R) traveled with the American Red Cross and demonstrated its technology in Washington, D.C. at the Red Cross National Headquarters; in Los Angeles at the California Science Center; in Atlanta, Ga., at the Turner Network Broadcast building; and in Detroit, at the Automotive Hall of Fame.

The culmination of the tour will take place at the Salt Palace in Salt Lake City on May 30 at the American Red Cross National Convention.

The Red Cross events featured technology demonstrations by IOMED and eight other companies whose various products are under consideration for use by the Red Cross. Numby Stuff eliminates the pain felt by most donors from insertion of the needle used to access the vein for blood donation.

"The invitation toexhibit at the American Red Cross' anniversary celebration presents us with a great opportunity," said Ned M. Weinshenker, Ph.D., president and chief executive officer of IOMED. "Local pain management was the objective behind the development of Numby Stuff and we hope that offering a pain-free needle insertion will encourage increased blood donations."

Developed by IOMED of Salt Lake City, Numby Stuff quickly and effectively delivers IONTOCAINE(R)(a), IOMED's anesthetic medication, directly into the skin using a mild, low-level electrical current from a small, battery-powered dose controller. Within 10-15 minutes, the area becomes numb, making procedures such as the needle insertion for blood donations painless for the vast majority of patients.

IOMED's iontophoretic drug delivery systems have been used for many years by physical therapists and sports medicine specialists to treat a wide variety of local acute inflammatory conditions. IOMED adapted the technique for anesthesia after realizing its potential to significantly reduce or eliminate the pain of needle insertions and a variety of other local dermatological procedures.

The American Red Cross is the largest provider of blood, plasma and tissue in the United States. It provides nearly half of the nation's donations by working with more than 4.5 million donors and 3,000 hospitals annually through its network of 38 blood regions. In addition, the 18 Red Cross tissue centers nationwide provide one quarter of the tissue donations for transplantations in the United States. -0-

Note to Editors: (a) IONTOCAINE(R) complete prescribing information available upon request.

IOMED, Inc., www.iomed.com is engaged in research, development, and manufacture of iontophoretic drug delivery systems to health care providers worldwide. Advanced research for local and systemic delivery of ionic pharmaceutical compounds to treat various medical conditions is conducted by its subsidiary, Dermion Inc. IOMED is based in Salt Lake City.

This press release may contain projections, estimates and statements which could be deemed "forward-looking statements" under applicable securities laws. These statements can be identified by the use of the terms such as "may," "will," and "expect." Such statements involve risks or uncertainties that could cause the actual results or performance of the company to be materially different from the results described therein.

COPYRIGHT 1998 Business Wire
COPYRIGHT 2004 Gale Group

Return to Iontocaine
Home Contact Resources Exchange Links ebay